Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04563026




Registration number
NCT04563026
Ethics application status
Date submitted
18/09/2020
Date registered
24/09/2020
Date last updated
26/02/2024

Titles & IDs
Public title
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
Scientific title
A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Alcoholic Hepatitis
Secondary ID [1] 0 0
C928-011
Universal Trial Number (UTN)
Trial acronym
AHFIRM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alcoholic Hepatitis 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - DUR-928 30 mg
Treatment: Drugs - DUR-928 90 mg
Treatment: Drugs - Placebo+ Standard of Care (SOC)

Experimental: DUR-928 (larsucosterol, 30 mg) -

Experimental: DUR-928 (larsucosterol, 90 mg) -

Placebo Comparator: (Placebo) Sterile Water for Injection -


Treatment: Drugs: DUR-928 30 mg
IV infusion

Treatment: Drugs: DUR-928 90 mg
IV infusion

Treatment: Drugs: Placebo+ Standard of Care (SOC)
IV infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Difference in 90-day mortality or liver transplant between IV DUR-928, 30 mg or 90 mg, and placebo.
Timepoint [1] 0 0
Day 90
Secondary outcome [1] 0 0
Difference in 90-day mortality between IV DUR-928, 30 mg or 90 mg, and placebo.
Timepoint [1] 0 0
Day 90
Secondary outcome [2] 0 0
Difference in 28-day mortality or liver transplant between IV DUR-928, 30 mg or 90 mg, and placebo.
Timepoint [2] 0 0
Day 28
Secondary outcome [3] 0 0
Difference in 28-day mortality between IV DUR-928, 30 mg or 90 mg, and placebo.
Timepoint [3] 0 0
Day 28

Eligibility
Key inclusion criteria
1. Able to provide written informed consent (either from subject or subject's legally
acceptable representative).

2. Onset of jaundice within prior 8 weeks.

3. Average daily consumption of >40 (females) or >60 (males) grams of alcohol for 6
months or longer, with < 8 weeks of abstinence before the onset of jaundice.

4. The determination of AH may be based on typical serum chemistry (as determined by
local laboratory) or liver biopsy at any time during the current episode of AH:

- Serum total bilirubin > 3.0 mg/dL

- 50 < AST < 400 IU/L

- ALT < 400 IU/L

- AST/ALT > 1.5

5. Maddrey discriminant function (MDF) = 32 assuming a control prothrombin time of 12
seconds.

6. Model for End-stage Liver Disease (MELD) score: 21-30.

7. Liver biopsy is not required, but may be used to confirm the diagnosis of AH at the
Investigator's discretion. Biopsy, if used as a diagnostic criterion, must have
occurred during the current episode.

8. Male or female subjects 18 years of age or older.

9. Subjects must agree to use effective methods to prevent pregnancy while participating
in the study.

10. Subjects must agree to participate in an alcohol abstinence support program
recommended by the local institution's addiction specialists.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Subjects taking systemic corticosteroids for a duration exceeding 8 days in the 30
days prior to screening.

2. Subjects experiencing or considered at high risk for alcohol withdrawal seizures or
delirium tremens.

3. Active infection (such as spontaneous bacterial peritonitis [SBP], urinary tract
infection [UTI], bacteremia, acute viral hepatitis, uncontrolled HIV, and active SARS
CoV2 infection).

4. Serum creatinine >2.5 mg/dL.

5. Subjects undergoing continuous veno-venous hemodialysis (CVVH).

6. Uncontrolled gastrointestinal bleeding.

7. A history of pre-admission refractory ascites defined as more than 4 paracenteses in
the previous 8 weeks despite diuretic therapy.

8. Liver biopsy (if carried out) with findings not compatible with AH.

9. Stage =3 hepatic encephalopathy by West Haven criteria.

10. Any severe concomitant cardiovascular, renal, endocrine, pulmonary, psychiatric
disorder, or multi-organ failure.

11. Other concomitant cause(s) of liver disease.

12. Any active malignancy or any malignancy diagnosed within the last five years other
than curable skin cancer (basal cell or squamous cell carcinomas).

13. Positive Urine Drug Screen (amphetamines, barbiturates, benzodiazepines, cocaine and
opiates) except THC and prescription medications.

14. Existing or intended pregnancy or breast feeding.

15. Participation in another interventional clinical trial within 30 days of Screening.

16. History of organ transplantation, other than a corneal transplant.

17. Underlying diseases that, in the opinion of the site investigator, might be
complicated or exacerbated by proposed treatments or might confound assessment of
study drug.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/01/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
6/09/2023
Sample size
Target
Accrual to date
Final
307
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [3] 0 0
Mater Health - Mater Hospital Brisbane - South Brisbane
Recruitment hospital [4] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [5] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [6] 0 0
Eastern Health - Box Hill Hospital - Box Hill
Recruitment hospital [7] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [8] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2217 - Kingswood
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment postcode(s) [5] 0 0
5042 - Bedford Park
Recruitment postcode(s) [6] 0 0
3128 - Box Hill
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment postcode(s) [8] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New Mexico
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
Austria
State/province [27] 0 0
Graz
Country [28] 0 0
Belgium
State/province [28] 0 0
Brussels
Country [29] 0 0
Belgium
State/province [29] 0 0
Edegem
Country [30] 0 0
France
State/province [30] 0 0
Besançon
Country [31] 0 0
France
State/province [31] 0 0
Lille
Country [32] 0 0
France
State/province [32] 0 0
Lyon
Country [33] 0 0
France
State/province [33] 0 0
Marseille
Country [34] 0 0
United Kingdom
State/province [34] 0 0
England
Country [35] 0 0
United Kingdom
State/province [35] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Durect
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
CTI Clinical Trial and Consulting Services
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating
Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic
Hepatitis (AH).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04563026
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Robert Gordon, MD, FACS
Address 0 0
CTI Clinical Trial and Consulting Services
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04563026